Company Filing History:
Years Active: 1993
Title: Viggo Kruse: Innovator in Diabetes Management
Introduction
Viggo Kruse is a notable inventor based in Skovlunde, Denmark. He has made significant contributions to the field of diabetes management through his innovative patent. His work focuses on improving the assessment of diabetes control, which is crucial for diabetic patients.
Latest Patents
Viggo Kruse holds a patent for the "Determination of glycated (glycosylated) hemoglobin in blood." This invention addresses the concentration of glycated hemoglobin, HbA.sub.1c, which is a valuable indicator of diabetes control. The patent describes a monoclonal antibody that specifically binds to HbA.sub.1c, allowing for its determination in blood samples without prior denaturation. This can be achieved through analytical methods such as radioimmunoassay or enzyme-linked immunosorbent assay. Additionally, the invention includes hybridoma cell lines that produce the monoclonal antibodies.
Career Highlights
Viggo Kruse is associated with Novo Industri A/S, a company known for its advancements in diabetes care and treatment. His work has contributed to the development of more effective diagnostic tools for monitoring diabetes.
Collaborations
Viggo has collaborated with notable colleagues, including Jesper Zeuthen and Annette Prento, who have also contributed to advancements in the field of diabetes management.
Conclusion
Viggo Kruse's innovative work in the determination of glycated hemoglobin has the potential to significantly enhance diabetes management. His contributions reflect the importance of research and innovation in improving healthcare outcomes for diabetic patients.